S-Quatre Corporation

S-Quatre Corporation is a dynamic biotechnology research company dedicated to harnessing the power of stem cells to develop innovative therapeutics. S-Quatre is focused on clinical-phase development, utilizing stem cells from baby tooth pulp to create groundbreaking treatments for conditions such as cerebral palsy, osteonecrosis of the femoral head, spinal cord injury, and brain cancer. The company's proprietary stem cells, known as SQ-SHED, are manufactured using a unique method that ensures exceptional growth capacity and the production of significantly higher levels of growth factors, particularly those related to nerve growth and angiogenesis, compared to other stem cells.

Located at 1-2-12, Shinkawa, Chuo-ku, Tokyo, 104-0033, JP, S-Quatre Corporation leverages the intrinsic growth capacity of child's cells and its specialized manufacturing process to produce millions of formulations from a single tooth. This innovative approach ensures a stable and sustainable product life-cycle without the need for donor changes. In addition to advancing its own pipeline, S-Quatre also provides a reliable supply service of GMP-grade SHED master cell banks, compliant with FDA guidelines, to pharmaceutical and biotechnology companies seeking high-quality cell materials for the development of various medical modalities.

S-Quatre Corporation is committed to pushing the boundaries of biotechnology research to improve patient outcomes and transform the treatment landscape for challenging medical conditions. We invite the management of S-Quatre Corporation to enhance their presence on our platform by creating a customized and exclusive company showcase and product listing, further highlighting their pioneering work in stem cell therapeutics.